BRIEF-Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration With Blackstone Life Sciences To Advance Phase 3 Development And Commercialization Of Zumilokibart

Apogee Therapeutics, Inc.
Blackstone Inc.

Apogee Therapeutics, Inc.

APGE

0.00

Blackstone Inc.

BX

0.00

May 27 (Reuters) - Apogee Therapeutics Inc APGE.O:

  • APOGEE THERAPEUTICS ANNOUNCES $1.3 BILLION STRATEGIC FINANCING COLLABORATION WITH BLACKSTONE LIFE SCIENCES TO ADVANCE PHASE 3 DEVELOPMENT AND COMMERCIALIZATION OF ZUMILOKIBART

  • APOGEE THERAPEUTICS INC - DEAL INCLUDES UP TO $800 MILLION SYNTHETIC ROYALTY AND UP TO $500 MILLION SENIOR DEBT

  • APOGEE THERAPEUTICS INC - BLACKSTONE TO PROVIDE UP TO $800 MILLION SYNTHETIC ROYALTY FUNDING FOR 15 YEARS

  • APOGEE THERAPEUTICS INC - REMOVES CASH RUNWAY END DATE GUIDANCE AFTER BLACKSTONE AGREEMENT

  • APOGEE THERAPEUTICS INC - UP TO $400 MILLION ADDITIONAL FUNDING AVAILABLE UPON FDA APPROVAL OF ZUMILOKIBART

  • APOGEE THERAPEUTICS INC - FIRST $400 MILLION PREAPPROVAL FUNDING IN 3 TRANCHES BASED ON DEVELOPMENT MILESTONES

Source text: ID:nGNX9TcsB6

Further company coverage: APGE.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.